protein
| sulfonylurea receptor 2A, SUR2A |
|
he two intracellular domains of Kir6.2 physically interact with each other |
|
Kir 6.1 to produce functional channels |
|
interacting with ANK2 (ANK2 has multiple roles in the active trafficking of KCNJ11 to the plasma membrane, as well as key roles in the retention and stabilization of KCNJ11 in relation to the plasma membrane and cytoskeleton) |
|
ABCC8 controls KCNJ11 gating by modulating KCNJ11 interactions with INPP5J |
|
slide helix elements that are required for functional channel expression and control of KCNJ11 gating by intracellular ATP |
|
SPTBN4–targeted CAMK2A directly phosphorylates the inwardly-rectifying potassium channel, KCNJ11 |
|
SPTBN4 is required for CAMK2D, ANK2, KCNJ11, and ABCC8 expression in beta cells |
|
KCNJ11 acts as an oncogene in hepatocellular carcinoma (HCC) though forming a complex with LDHA |
| mice expressing a dominant-negative form of the KATP channel subunit Kir6. 2 develop hypoglycemia with hyperinsulinemia in neonates and hyperglycemia with hypoinsulinemia and decreased beta cell population in adults | |
transgenic mice expressing beta cell K(ATP) channels with reduced ATP sensitivity develop severe hyperglycemia, hypoinsulinemia, and ketoacidosis and die within 5 days |
|
mice lacking the Kir6.2 subunit of K(ATP) channels are susceptible to generalized seizures after brief hypoxia |
|
mouse expressing a Kir6.2 mutation (V59M) specifically in pancreatic beta cells develop severe diabetes soon after birth and display a reduced percentage of beta cells with abnormal morphology and lower insulin content |
|
mice carrying a human Kir6.2 mutation (Val59-->Met59) targeted to either muscle or nerve display motor impairments originate in the central nervous system rather than in muscle or peripheral nerves |